Company: SNWV
Filing Date: 2025-08-07
Form Type: 10-Q
Source: 0001628280-25-038937
Chunk: 38

Company: SANUWAVE Health, Inc.
Filing Date: 2025-08-07
Form: 10-Q
Item: Part I, Item 1
Chunk 38
---
 factoring, net- 831 Payments of principal on finance leases(149)(140)Net Cash Flows Provided by Financing Activities104 316 Effect of Exchange Rates on Cash- 121 Net Change in Cash During Period(1,741)663 Cash at Beginning of Period10,237 1,797 Cash at End of Period$8,496 $2,460 

8

Supplemental Information:Cash paid for interest$2,255 $2,055 Non-cash Investing and Financing Activities:Capitalize interest into senior secured debt407 3,850 Shares granted in lieu of board of director fees77 - Stock options granted in lieu of cash bonus117 - Right-of-use assets obtained in exchange for lease liabilities430 - RSUs granted in exchange for services10 - Warrants issued in conjunction with convertible promissory notes - 3,633 Conversion of asset-backed secured promissory notes to convertible promissory notes- 4,584 Shares issued for settlement of debt- 1,412 Write off deferred merger costs- 1,226 

The accompanying notes to condensed consolidated financial statements are an integral part of these financial statements.

9

SANUWAVE HEALTH, INC. AND SUBSIDIARIES

NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

June 30, 2025

1.        Nature of the Business and Basis of Presentation

SANUWAVE Health, Inc. and subsidiaries (“SANUWAVE” or the “Company”) is focused on the commercialization of its patented regenerative medicine utilizing noninvasive ultrasound or shockwaves to produce a biological response promoting the repair and regeneration of tissue, musculoskeletal, and vascular structures.Basis of Presentation - The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 8-03 of Regulation S-X. Accordingly, these condensed consolidated financial statements do not include all the information and disclosures required by U.S. GAAP for comprehensive financial statements. The financial information as of June 30, 2025, and for the three and six months ended June 30, 2025, and 2024 is unaudited; however, in the opinion of management, all adjustments (